cyrilzakka/clinical-trials huggingface dataset:
Opioid Free Anesthesia in Maxillofacial Surgery

Opioid free anesthesia is a promising practice in anesthesia. Studies already carried out have compared OFA to an opioid or "opioid anesthesia" (OA) protocol without the use of antihyperalgesic in the OA protocol. Most of the studies currently available have been carried out in Europe, America and a few in Asia under conditions other than those available in precarious situations.That's why we decide to conduct a study to evaluate the effectiveness of an OFA protocol in maxillofacial surgery in Burkina Faso.

The patients were recruited at the University Hospital of Souro Sanou in Bobo Dioulasso

Eligibility Criteria:
Inclusion Criteria:

* All patients aged between 15 and 65 years, admitted to the central operating room of the hospital for maxillofacial surgery.

Exclusion Criteria:

* Known or suspected coronary artery disease on preoperative consultation;
* Unstable arterial hypertension
* Insulin-dependent diabetes
* Second degree atrioventricular block
* Neuro-vegetative dysautonomia;
* known allergy or intolerance to a drug of the protocols
The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment

The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcinoma (HCC) patients treated with minimally invasive treatment. The correlation between prognosis-related MRI features and pathological features was studied through artificial intelligence method, so as to provide the interpretability of image features for predicting the prognosis of HCC patients treated with minimally invasive treatment.

The prognosis prediction of early stage hepatocellular carcinoma (HCC) after minimally invasive treatment involves clinical decision of treatment and follow-up. Magnetic resonance imaging (MRI) has become the main approach for monitoring and following up of HCC, however it's difficult to predict HCC prognosis before surgery. We found the following limitations among previous researches: multimodal MRI using different sequences shows uncertain boundaries of HCC, which makes precise segmentation more difficult, and also leads to an additional workload for extracting high throughput radiomics features, which are limited in quantity and repeatability. Regarding to prognosis aspect, the MRI images, clinical data, and follow up information have not been fully exploited yet. In addition, the prognosis result obtained by radiomics workflow is difficult to be explained and applied to clinical application. Therefore, we conduct a study to solve the problems mentioned above: (1) To explore an effective deep learning neural network method and a pre-training model for improving tumor segmentation accuracy. (2) To establish a method for extracting high-throughput multi-dimensional and multimodal MRI radiomics features related to HCC prognosis. (3) To explore a correlation between "multimodal MRI based pathological features of early stage HCC" and the results of "multimodal MRI based prognosis depth network of early stage HCC after minimally invasive treatment". Based on above approaches, we aim to establish "multimodal MRI based prognosis model of early stage HCC after minimally invasive treatment" in different clinical application scenarios guiding to clinical decision-making. Moreover, we also aim to explore the correlation between MRI radiomics features and pathology, which provides theoretical foundations for the MRI radiomics based pathological researches.

Eligibility Criteria:
Inclusion Criteria:

* Hepatocellular carcinoma patients received minimally invasive treatment (transcatheter arterial chemoembolization, radiofrequency ablation, or combined) or hepatectomy;
* Patients received MRI examination within 1 month before treatment;
* Complete post-treatment prognosis information.

Exclusion Criteria:

* local or systemic treatment before MR examination;
* Incomplete clinical and pathological data;
* Heavy image artifacts.
Role of CT Perfusion in Predicting Poor Outcome After Subarachnoid Hemorrhage

Prospective evaluation of patients with subarachnoid hemorrhage (SAH) will be done by computed tomography angiography (CTA) and perfusion imaging (CTP) for any correlation between degree of vasospasm and perfusion deficit as well as evaluating the ability of CTP to predict delayed cerebral ischemia.

Cerebral vasospasm is a serious complication of subarachnoid haemorrhage . In the first 2 weeks of SAH, angiographic vasospasm is seen up to 40-70% of patients and causes ischemic deficits in 15-36% of patients.

The best clinical indicator of significantly reduced brain perfusion (cerebral blood flow (CBF)\<20 ml per 100 g/min) is the presence of new neurologic deficits. However, clinical symptoms may be vague and mimic other conditions in patients with SAH.

CT Perfusion can be used in the evaluation of patients with possible vasospasm after subarachnoid hemorrhage (SAH). It can thus be used to assess cerebral ischemia and infarction as a result of vasospasm after SAH.

The presence of cerebral vasospasm identified with transcranial Doppler, digital subtraction angiography, or CT angiography (CTA) is frequently used to confirm DCI. Presence of vasospasm, however, does not prove the presence of ischemia and absence of vasospasm does not rule out. Better diagnostic tests in the acute stage of deterioration, possibly caused by DCI, are therefore needed. In patients with SAH, CTP has recently been shown to be promising for detection of early ischemia.

Eligibility Criteria:
Inclusion Criteria:

* All patients presented with subarachnoid haemorrhage

Exclusion Criteria:

* Patients with abnormal renal functions with creatinine ≥ 2 mg/dl/
* Patients with hypersensitivity to contrast media.
* Contraindication to radiation as pregnancy.
Collection of Biological Samples With Clinical Characterization of Covid-19 Patients

Biological collection (blood sample) associated with clinical data from Covid-19 patients

SARS-Cov2 is an emerging respiratory virus in the coronavirus family, responsible of the pandemic since November 2019. France, which has more than 17,000 deaths from the virus, is one of the main outbreaks. As of 16 April 2020, more than 76,000 individuals in France have been hospitalized, corresponding to 69% of confirmed cases (https://www.santepubliquefrance.fr).

Most affected patients have more or less marked clinical signs associating fever, cough, dyspnea, myalgia, anosmia, ageusia, digestive disorders. In some cases, the progression is worse with lung disease of varying severity. Indications for hospitalization are essentially the severe forms of Covid-19 disease, characterized by hypoxemic lung disease.

Risk factors for developing severe Covid-19 disease have been identified already: age, co-morbidity such as diabetes, obesity-overweight or cardiovascular diseases. It is assumed that other host-related factors, including genetics, may contribute to the existence of this phenotypic heterogeneity. At present, these factors are not known.

The objective of this research is to constitute a DNA collection from patients with Covid-19, in order to be able to search for genetic factors modulating the clinical phenotype.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of COVID-19 confirmed on RT-PCR test or chest scanner
* Any age
* Membership in the general social security system
* Inform consent signed by the patient or by legal representatives for minors

Exclusion Criteria:

* Refusal of the patient or one of the legal representatives
The Effect of Breathing Exercise Applied to Intensive Care Nurses on Fatigue and Perceived Stress

The aim of this randomized controlled trial was to investigate the effect of breathing exercise on fatigue and stress in intensive care nurses.

Hypotheses of the study; H11: The level of perceived stress in nurses practicing breathing exercise is lower than the nurses in the control group.

H12: The level of fatigue is lower in nurses practicing breathing exercise compared to nurses in the control group.

Data will be collected in the intervention and control groups with a pre-test data collection form before the intervention. Patients in the intervention group will be given breathing exercises, while patients in the control group will not receive any intervention. In the second week, interim follow-up data will be collected with the data collection form. At the end of the study; data will be collected from the intervention and control groups with post-test data collection forms.

In line with the randomization list, nurses will be assigned to the intervention and control groups in line with the inclusion criteria. The nurses will be informed about the study and their written and verbal consent will be obtained to participate in the study. Data will be collected from the nurses in the intervention and control groups with a pre-test data collection form. The nurses in the intervention group will be given breathing exercise practice, while the patients in the control group will not be subjected to any intervention. In the research; triple breathing technique (full yogic breathing) and 4-7-8 breathing technique will be used. In the intervention group, the nurses will first be told face-to-face about the breathing practice and have them do it. Then, face-to-face practice will be done three days a week, and on the other days, an audio recording of the breathing exercise will be sent by the researcher to the nurses via WhatsApp and they will be practiced daily. Breathing exercise will continue for 30 days in the intervention group. Follow-up data will be collected from the control and intervention group on the 15th day as an interim follow-up (with Piper fatigue scale and perceived stress scale). On the 30th day, the research will be finalized by collecting the post-test data. At the end of the study, the nurses in the control group will be shown and practiced breathing exercises.

Eligibility Criteria:
Inclusion Criteria:

* Working in intensive care for at least 6 months
* Volunteering to participate in the research
* Not practicing any complementary therapies during the study, such as breathing exercises, acupuncture, massage therapy, relaxation techniques and yoga, which may be effective on perceived stress and fatigue

Exclusion Criteria:

* Having a problem that prevents nasal breathing and prevents breathing exercises
* Being pregnant
* Experiencing physical and mental health problems that prevent communication
Submandibular Gland Preservation in Neck Dissection

Trial design: a randomized controlled trial.

Eligibility criteria for participants: patients with primary early stage oral squamous cell carcinoma. Exclusion criteria: cancer of the floor of the mouth.

Interventions: submandibular gland is preserved during neck dissection for patients of the experimental group; submandibular gland is removed during neck dissection for patients of the control group.

Primary Parameters: survival rate, mortality rate


Eligibility Criteria:
Inclusion Criteria:

Primary oral squamous cell carcinoma of early stage (T1N0 and T2N0).

Exclusion Criteria:

Cancer of the floor of the mouth.
Hospital to Home Study: Trial to Optimize Transitions and Address Disparities in Asthma Care

Caregiver-child dyads will be recruited during child's hospital admission for asthma exacerbation. Recruitment sites will be mainly Children's National Hospital Sheikh Zayed campus, as well as regional partners: Holy Cross Hospital, and Mary Washington Hospital. After enrollment, baseline data will be collected from caregiver. Caregiver-child dyads will be randomized (1:1 ratio) into the control arm or intervention arm. Control arm will receive the standard of care after hospital discharge. Intervention arm will receive the SOC plus an asthma navigator support after hospital discharge. Caregivers in both arms will complete data collection surveys (either in-person or via telehealth) at 3-,6-, 9-, and 12- month post enrollment.


Eligibility Criteria:
Inclusion Criteria:

1. speak English or Spanish
2. are at least 18 years old
3. live in the District of Columbia, Maryland, or Virginia (DMV)
4. have a child aged 4-12 years who is hospitalized due to asthma exacerbation.

Exclusion Criteria:

1. . Children ages 4-12 years with chronic medical condition (other than asthma) including but not limited to diabetes, sickle cell disease, heart disease, lung disease or neurological disorder
2. . Children ages 4-12 years involved in interventions with behavioral component and/or novel asthma therapeutics will be excluded given overlap with the current intervention
3. . Children ages 4-12 years in foster care
4. . Families not residing in the DMV
5. . Caregivers who do not speak English or Spanish
Evaluation of the Use of Cap in Improving the Performance of Colonoscopy

The aim of this study is to compare the colonoscopy success rate, cecal time and polyp detection rate between cap-fitted colonoscopy and conventional colonoscopy.

Colonoscopic examination has been used in clinical practice for approximately 40 years. Despite the fact that colonoscopy is widely available and is performed by many experienced colonoscopists there are concerns about the quality of colonoscopy as measured by several technical endpoints such as rate of failed caecal intubation and polyp miss rate. A large population-based study revealed 13.1% of colonoscopies failed to reach the cecum. In addition, one large review of back-to-back colonoscopies showed polyp miss rates of 24% for adenoma.

One potentially promising technique is cap-assisted colonoscopy. A transparent cap (or "hood") is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. Several randomized trials from Japan have mixed results regarding improved cecal intubation times and polyp detection rates. A recent large study from Hong Kong showed improved time to cecum but a reduced polyp detection rate. To date there is no large randomized study using the cap in a western population, in whom the colorectal cancer (CRC) incidence is known to be higher. We plan to conduct a randomized controlled trial to investigate the usefulness of cap-assisted colonoscopy in a Western population.

Eligibility Criteria:
Inclusion Criteria:

* All colonoscopy patients referred for colonoscopy at Royal Prince Alfred Hospital.

Exclusion Criteria:

* Prior colonic resection
* Pregnancy.
* Severe co-morbidities.
* Tertiary referral for endo-mucosal resection.
* Acute surgical conditions such as severe colitis, toxic megacolon, ischemic colitis, acute gastrointestinal bleeding.
Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States

The purpose of this study is to estimate the effectiveness of maternal immunization with Boostrix at preventing pertussis in infants in the United States.


Eligibility Criteria:
Inclusion Criteria:

Inclusion criteria for case infants:

* Case infants were eligible for the enrolment if they:
* were at least 2 days old and \< 2 months old on the cough onset date
* resided in the catchment area on their cough onset date
* were born in a hospital in their state of residence
* were ≥37 weeks' gestational age at birth
* were neither adopted nor in foster care
* did not live in a residential care facility

Inclusion criteria for control infants:

* Control infants were eligible for the enrolment if they:
* were at least 2 days old and \<2 months old on the case infant's cough onset date
* were born in a hospital in their state of residence
* were ≥37 weeks' gestational age at birth
* were neither adopted nor in foster care
* did not live in a residential care facility
* were born at the same hospital as the case infant

did not have pertussis diagnosis prior to the cough onset date of the corresponding case infant

Exclusion Criteria:

* Infants (case and controls) whose mothers have received Adacel or mothers without brand information available, as well as controls who were matched to a case whose mother received Adacel or mothers without brand information available, will be excluded from the analysis of the effectiveness of vaccination with Boostrix.
Masseter Muscle Activity and Post-operative Pain in a Group of Egyptian Children Treated With Hall Technique Vs Modified Hall Technique

The study aims to evaluate postoperative pain and masseter muscle activity in a group of Egyptian children with carious primary molars treated with Hall Vs modified Hall Technique (with proximal and occlusal reduction).


Eligibility Criteria:
Inclusion Criteria:

* Children 5-7 years with carious lower second primary molars
* Both genders.
* Systemically and mentally healthy.

Exclusion Criteria:

* History of systemic or mental conditions.
* Special health care needs who require pharmacological management before dental treatment.
* Acute dental pain or trauma.
* Extremely uncooperative children who require being treated under general anesthesia.
Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

This pilot study will examine the benefit of this amino acid based hydration solution in patients with IBD who have undergone a total colectomy and have either ileostomies or jpouches. Findings from this study and possible future studies could have broad implications for patients with malabsorption resulting from many underlying conditions, including IBD.

Eligibility Criteria:
Inclusion Criteria:

1. Colectomy with ileostomy

   a. Ileostomy alone with less than 30 cm of small bowel resected i. A diverting ileostomy is permitted
2. Stable disease activity with no or mild inflammation felt not to significantly impact gastrointestinal (GI) output.
3. Any of the following:

   1. Need for IV fluids \>2x/month
   2. Intake of \> 1.5 liters of oral fluid daily
4. GI output of \> 1.3 liters in a 24-hour period for three days each week during a 14 day screening period (does not need to be consecutive days)
5. Stable doses of anti-diarrheal agents, octreotide or Gattex
6. Stable doses of anti-inflammatory agents and/or antibiotics
7. Willing to comply with study visits and assessments, including product intake.

Exclusion:

1. Chronic renal insufficiency glomerular filtration rate (GFR) \< 40
2. Significant chronic liver disease altering fluid balance
3. Uncontrolled flare of inflammatory disease

   a. (Inflammation can be present but at a stable at least partly controlled level) b. An anticipated change in medication in the next 3 months i. May be included 8 weeks after changing medications if they are stable c. Anticipated gastrointestinal surgery in the subsequent 3 months i. May be included if they are 4 months out from surgery and stable
4. Diabetes
5. Use of Lactulose/Mannitol solution is contraindicated
6. Current Diagnosis of Cancer

   a. May be included if they are 4 or more months out from cancer therapy (i.e. chemotherapy, etc.)
7. Aversion to the taste of enterade® or inability to take the product as instructed
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy

RATIONALE: Physical activity may help lessen fatigue caused by cancer in patients receiving chemotherapy. It is not yet known whether a home-based walking and resistance-band exercise program is effective in lessening fatigue.

PURPOSE: This randomized phase III trial is studying how well exercise works in lessening fatigue caused by cancer in patients undergoing chemotherapy.

OBJECTIVES:

Primary

* Determine the efficacy of a home-based walking and progressive-resistance exercise program in reducing cancer-related fatigue (CRF) in patients undergoing chemotherapy.

OUTLINE: This is a multicenter study. Patients are stratified according to participating site, chemotherapy course length (2 weeks vs 3 weeks), gender, and degree of fatigue reported on the study assessment questionnaire (≤ 5 vs \> 5). Patients are randomized to 1 of 2 intervention arms.

* Arm I: Patients receive standard chemotherapy.
* Arm II: Patients receive a home-based walking kit comprising an Exercise for Cancer Patients Manual, a pedometer, and therapeutic resistance bands. Patients undergo moderately intense aerobic exercise (walking) monitored by a pedometer, and low to moderately intense progressive-resistance exercise using therapeutic resistance bands for 6 weeks. Patients also receive standard chemotherapy.

Patients in both arms undergo assessment of their aerobic capacity and strength by the 6-minute walk test and handgrip dynamometry at baseline and at day 41. They also have a fasting blood draw and wear an actigraph for one week at baseline and week 6. Patients complete Functional Assessment of Chronic Illness Therapy-Fatigue and -Cognitive Subscales, Brief Fatigue Inventory, Multidimensional Fatigue Symptom Inventory, Center for Epidemiological Studies-Depression Scale State Trait Anxiety Inventory, Pittsburgh Sleep Quality Inventory, Profile of Mood States, Aerobic Center Longitudinal Study Physical Activity, and Symptom Inventory questionnaires at baseline and at day 41 and keep a daily exercise diary during study intervention.

Eligibility Criteria:
Inclusion criteria:

* primary diagnosis of cancer other than leukemia, with no distant metastasis
* chemotherapy naïve
* starting chemotherapy treatments for cancer and scheduled for at least 6 weeks of treatments with treatment cycles of either 2, 3 or 4 weeks. Oral chemotherapy (e.g., Xeloda) is acceptable
* Karnofsky Performance level of 70 or greater
* able to read English

Exclusion criteria:

* diagnosis of leukemia
* metastatic disease
* receiving concurrent radiation therapy
* physical limitations (e.g., cardiorespiratory, orthopedic, central nervous system) that contraindicate participation in a low to moderate intensity home-based walking and progressive resistance program
* identified as in the active or maintenance stage of exercise behavior as assessed by the Exercise Stages of Change Short Form
Comparison of Digital Breast Tomosynthesis to Conventional Mammography

In March 2009, Health Canada approved Tomosynthesis for use in screening and diagnosis of breast cancer. The Tomosynthesis technology is designed as a complementary imaging model that is incorporated into the 2D Mammography system. This new imaging system has the capability to provide 2D, 3D and combination mode models. It consists of generating thin slice images that can be viewed individually as multiple images from the same breast. Tomosynthesis provides improved visibility of possible lesions within the breast. The study aims to compare the performance of Tomosynthesis to the conventional Digital Mammography in detecting and characterizing suspicious findings in subjects who will be having breast biopsies.


Eligibility Criteria:
Inclusion Criteria:

* Subject is female of any race and ethnicity
* Following routine mammography imaging, subject is categorized as Breast Imaging Reporting and Data System (BI-RADS®) 4 or 5 because of calcifications / masses and architectural distortion will undergo study imaging within 30 days of routine imaging
* Subject will undergo 2D/3D digital breast tomosynthesis prior to biopsy

Exclusion Criteria:

* Subject unable or unwilling to undergo informed consent
* Subjects who are unable or unwilling to tolerate compression
* Subjects who are pregnant or who think they may be pregnant
* Subjects who are breast-feeding
* The subject is too large to be imaged on the large 24 x 30 cm detector